Collegium Pharmaceutical, Inc. COLL Symproic — Cost
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s symproic — cost.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s symproic — cost?
- Collegium Pharmaceutical, Inc. (COLL) reported symproic — cost of $70M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s symproic — cost changed year-over-year?
- Collegium Pharmaceutical, Inc.'s symproic — cost decreased by 0.0% year-over-year, from $70M to $70M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic — cost?
- Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s symproic — cost has grown at a 0.0% compound annual growth rate (CAGR), from $280M to $280M.
- What does symproic — cost mean?
- Reflects the direct costs associated with the production, manufacturing, and distribution of the Symproic product. Monitoring this helps evaluate the gross margin efficiency and cost-management effectiveness for this specific segment.